https://www.selleckchem.com/products/KU-55933.html
entry (1.00 ± 0.37 vs. 0.46 ± 0.12, t = 2.42, P less then 0.05) and viral replication (1.00 ± 0.43 vs. [6.18 ± 0.95] × 10, t = 3.98, P less then 0.05). CONCLUSIONS Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and clinical trial of CEP for treatment of 2019-nCoV infection is warranted.BACKGROUND Regulatory policy (R
Like
Comment
Share
